SBPV04
BCRP Human Vesicular Transport Kit
membrane based kit for Human BCRP Vesicular Transport Assays
Synonym(s):
ABCG2, Breast Cancer Resistance Protein
Product Name
BCRP Human Vesicular Transport Kit, membrane based kit for Human BCRP Vesicular Transport Assays
recombinant
expressed in human cells
UniProt accession no.
shipped in
dry ice
storage temp.
−70°C
Gene Information
human ... ABCG2(9429)
Application
The PREDIVEZTM Vesicular Transport Kit is a simple and powerful tool to investigate drug transporter interactions. It provides information on any interaction between the ABC transporter and the drug candidate that would affect the transport of the fluorescent or radiolabeled or cold.
PREDIVEZTM vesicular transport kits are available in three sizes 3, 6 or 9 compound sizes. The kits contain the sufficient amount of reagents and membrane preparations needed for the testing of 3 compounds per 96-well plate. Each kit is accompanied by a CD that includes the assay protocol, an Excel spreadsheet with a data processing template, SDS and the inhibition curves with reference compounds.
PREDIVEZTM vesicular transport kits are available in three sizes 3, 6 or 9 compound sizes. The kits contain the sufficient amount of reagents and membrane preparations needed for the testing of 3 compounds per 96-well plate. Each kit is accompanied by a CD that includes the assay protocol, an Excel spreadsheet with a data processing template, SDS and the inhibition curves with reference compounds.
General description
SOLVO Biotechnology offers ready-to-use assay kits for efflux and uptake transporters. SOLVO′s PREDIVEZ Vesicular Transport Assay Kits are suitable for efflux transporter inhibition studies. The kits are designed to test the inhibitory effect of one or more test compounds on the vesicular transport of a probe substrate. In most cases a fluorescent probe substrate is included. Kits contain all reagents and solutions necessary to conduct the drug-transporter interaction assay of need.
Legal Information
Distributed for SOLVO Biotechnology, Inc.
Physical form
Supplied as frozen membrane vesicles, containing 5 mg/ml membrane protein, labeled with volume, catalog number (transporter), date of production, protocols and necessary reagents sufficent for the analysis of 3, 6, or 9 test compounds
signalword
Danger
Hazard Classifications
Carc. 2 - Eye Dam. 1 - Lact. - Met. Corr. 1 - Repr. 1A - Skin Corr. 1B
Storage Class
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
flash_point_f
Not applicable
flash_point_c
Not applicable
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Márton Jani et al.
Journal of pharmaceutical sciences, 100(1), 94-97 (2010-06-25)
Ivermectin is an antiparasitic drug frequently administered to humans. It has a limited brain exposure that is attributed to the efflux activity of ABCB1/Abcb1. ABCG2/Abcg2 is also a major transporter present in most pharmacologically important barriers. However, interaction of ivermectin
Albert Mennone et al.
Drug metabolism and disposition: the biological fate of chemicals, 38(10), 1673-1678 (2010-07-06)
Breast cancer resistance protein (Bcrp) is a member of the ATP-binding cassette membrane transporter family, which is expressed apically in liver, kidney, and intestine epithelium. Recent reports suggest that in addition to xenobiotics, porphyrins, and food toxins, Bcrp can also
Márton Jani et al.
Biological & pharmaceutical bulletin, 32(3), 497-499 (2009-03-03)
The pharmacokinetics of sulfasalazine, an anti-inflammatory drug is influenced by ATP-binding cassette G2 (ABCG2) (breast cancer resistance protein (BCRP), mitoxantrone resistance protein (MXR)) both in vitro and clinically. Due to its low passive permeability, the intracellular concentration of sulfasalazine is
E Kis et al.
Annals of the rheumatic diseases, 68(7), 1201-1207 (2008-04-10)
Earlier publications have suggested a possible role for the efflux transporter breast cancer resistance protein (BCRP) in acquired resistance to disease-modifying antirheumatic drugs (DMARDs) such as leflunomide and its metabolite A771726 (teriflunomide). However, there is no direct evidence that BCRP
M Maliepaard et al.
Cancer research, 61(8), 3458-3464 (2001-04-20)
High expression of the Breast Cancer Resistance Protein (BCRP) gene has been shown to be involved in resistance to chemotherapeutic drugs. Knowledge of the localization of BCRP protein in normal tissues may help unravel the normal function of this protein.
Related Content
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service